期刊文献+

抗骨质疏松药物临床应用的进展 被引量:18

Advances of anti-osteoporosis drugs in clinical application
下载PDF
导出
摘要 骨质疏松症是一种常见的老年性疾病。近年来,随着对该病的病因及致病机制的深入研究,出现了多种抗骨质疏松药物,许多已在临床广泛应用。但是,在临床应用中发现,没有任何一种药物可以完全替代其他药物而取得满意的疗效,且每种药物都存在一定的缺陷。文章主要对抑制骨吸收,促进骨形成和骨矿化物3类药物进行探讨,分析它们的作用机制、临床应用研究新进展以及各自的不良反应,以指导临床选择针对性药物及联合用药,避免出现严重的不良反应,并寻找进一步研究方向。 Osteoporosis is a common disease in the elderly. As studies on its causation and pathogenic mechanism deepened in recent years, there appeared many anti-osteoporotics and many of them had been widely used in clinic. However, none of them was found to be able to completely replace other drugs to achieve satisfactory effect in clinical applications. They all have certain defects. In this paper, three types of drugs including bone resorption inhibitors, bone mineralizers and bone formation accelerators were analyzed in terms of their mechanisms of action, advances in clinical application as well as their side effects, so as to guide the clinical choice and combination of drugs targeted to avoid serious side effects and to seek for the direction of further study.
出处 《中国组织工程研究与临床康复》 CAS CSCD 北大核心 2009年第46期9163-9166,共4页 Journal of Clinical Rehabilitative Tissue Engineering Research
  • 相关文献

参考文献27

  • 1Lindsay R, Hart DM, Clark DM.The minimum effective dose of estrogen for prevention of postmenopausal bone Ioss.Obstet Gynecol.1984;63(6):759-763.
  • 2The Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal Woman: principle results from the Woman's Health Initiative randomized controlled trial. Jama.2002; 288:321-333.
  • 3Kanis JA, Johnell O, Black DM, et al. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial.Bone. 2003;33(3):293-300.
  • 4Moffett AH,Ettinger M,Bolognese M,et aI.Lasofoxifene,a next,generation SERM,is effective in preventing loss of BMD and reducing LDL-C in postmenopausal women.J Bone Miner Res. 2004;19:S1:SA426.
  • 5Barham M.Selective estrogen-receptor modulators. N Engl J Med 2003;348(22):2259.
  • 6Acconcia F, Barnes C J, Kumar R.Estrogen and tamoxifen induce cytoskeletal remodeling and migration in endometrial cancer cells Endocrinology. 2006;147(3): 1203-1212.
  • 7Nalbandian G, Paharkova-Vatchkova V, Mao A, et al. The selective estrogen receptor modulators, tamoxifen and raloxifene, impair dendritic cell differentiation and activation. J Immunol. 2005; 175(4): 2666-2675.
  • 8Mao A, Paharkova-Vatchkova V, Hardy J, et al. Estrogen selectively promotes the differentiation of dendritic cells with characteristics of Langerhans cells. J Immunol. 2005;175(8):5146-5151.
  • 9Hooper M J, Ebeling PR, Roberts AP, et al. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial. Climacteric. 2005;8(3):251-262.
  • 10Nguyen ND, Eisman JA, Nguyen TV.Anti-hip fracture efficacy of biophosphonates: a Bayesian analysis of clinical trials.J Bone Miner Res. 2006;21(2):340-349.

二级参考文献22

  • 1Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal woman with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of Raloxifene Evalu ation (MORE) Investigato
  • 2Lippman ME, Kreuger KA, Eckert S, et al. Indicators of lifetime estrogenexposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study patientsl[ J ]. J Clin Oncol, 2001, 19:3111
  • 3Uesugi T, Toda T, Tsuji K, et al. Comparative study on reduction of bone loss and lipid metabolism abnormality in ovariectomized rats by soy flavones daidzin genistin and glytin[J]. BiolPharm Bull, 2001, 24:368-372
  • 4The Writing group for the women's Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal woman: principleresults from the Woman's Health Initiative randomized controlled trial[ J ].JAMA, 2002, 288:321-333
  • 5Kanis JA. Treatment of osteoporiosis in elderly women[J]. Am J Med, 1995,98 (Suppl 2A) :60-66
  • 6Kiel DP, Felsom P T, Anderson J J, et al. Hip fractureand the use of estrogen in postmenopausal women: the Framingham study[J]. N Engl Med, 1987,317:1169-1174
  • 7Potter SM, Baum JM, Teng H, et al. Soy protein and isoflavone: their ef fects on blood lipids and bone, density in postmenopausal women[J]. Am J Clin Nutr , 1998,68(Suppl) :S1375-1379
  • 8Alekel DC, Germain AS, Peterson CT, et al. Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women[ J ]. Am J Clin Nutr, 2000, 72:844-852
  • 9Amin S, La Valley MP, Simms RN, et al. The role of vitamin D in corticosteroid-induced osteoporosis: a meta- analytic approach[J]. Arthritis Rheum, 1999, 42:1740-1751
  • 10Hock JM, Gera I. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone [J]. J Bone Miner Res, 1992, 7:65-72

共引文献17

同被引文献298

引证文献18

二级引证文献127

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部